CMChristopher Mehlin

Christopher Mehlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Mehlin has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies

    by Anilkumar Gopalakrishnapillai, Colin E. Correnti, Kristina Pilat, Ida Lin, Man Kid Chan, Ashok D. Bandaranayake, Christopher Mehlin, Anne Kisielewski, Darcy Hamill, Allison J. Kaeding, et al.

    Advances in the treatment of pediatric AML have been modest over the past four decades. Despite maximally intensive therapy, approximately 40% of patients will relapse. Novel targeted therapies are needed to improve outcomes. We identified mesothelin (MSLN), a well-validated target overexpressed in some adult malignancies, to be highly expressed on the leukemic cell surface in a subset of pediatric AML patients. The lack of expression on normal bone marrow cells makes MSLN a viable target for immunotherapies such as T-cell engaging bispecific antibodies (BsAbs) that combine two distinct antibody-variable regions into a single molecule targeting a cancer-specific antigen and the T-cell co-receptor CD3. Using antibody single-chain variable region (scFv) sequences derived from amatuximab-recognizing MSLN, and from either blinatumomab or AMG330 targeting CD3, we engineered and expressed two MSLN/CD3-targeting BsAbs: MSLNAMA-CD3L2K and MSLNAMA-CD3AMG, respectively. Both BsAbs promoted T-cell activation and reduced leukemic burden in MV4;11:MSLN xenografted mice, but not in those transplanted with MSLN-negative parental MV4;11 cells. MSLNAMA-CD3AMG induced complete remission in NTPL-146 and DF-5 patient-derived xenograft models. These data validate the in vivo efficacy and specificity of MSLN-targeting BsAbs. Because prior MSLN-directed therapies appeared safe in humans, MSLN-targeting BsAbs could be ideal immunotherapies for MSLN-positive pediatric AML patients.


  • A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposure

    by Michelle L. Cook Sangar, Emily J. Girard, Gene Hopping, Chunfeng Yin, Fiona Pakiam, Mi-Youn Brusniak, Elizabeth Nguyen, Raymond Ruff, Mesfin M. Gewe, Kelly Byrnes-Blake, et al.

    A scorpion-derived peptide-steroid conjugate accumulates in cartilage and reverses inflammation in a rat model of arthritis without steroid toxicity.


  • Screening, large-scale production and structure-based classification of cystine-dense peptides

    by Colin E. Correnti, Mesfin M. Gewe, Christopher Mehlin, Ashok D. Bandaranayake, William A. Johnsen, Peter B. Rupert, Mi-Youn Brusniak, Midori Clarke, Skyler E. Burke, Willem De Van Der Schueren, et al.

    Peptides folded through interwoven disulfides display extreme biochemical properties and unique medicinal potential. However, their exploitation has been hampered by the limited amounts isolatable from natural sources and the expense of chemical synthesis. We developed reliable biological methods for high-throughput expression, screening and large-scale production of these peptides: 46 were successfully produced in multimilligram quantities, and >600 more were deemed expressible through stringent screening criteria. Many showed extreme resistance to temperature, proteolysis and/or reduction, and all displayed inhibitory activity against at least 1 of 20 ion channels tested, thus confirming their biological functionality. Crystal structures of 12 confirmed proper cystine topology and the utility of crystallography to study these molecules but also highlighted the need for rational classification. Previous categorization attempts have focused on limited subsets featuring distinct motifs. Here we present a global definition, classification and analysis of >700 structures of cystine-dense peptides, providing a unifying framework for these molecules.


  • Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

    by Colin E. Correnti, George S. Laszlo, Willem J. de van der Schueren, Colin D. Godwin, Ashok Bandaranayake, Melanie A. Busch, Chelsea J. Gudgeon, Olivia M. Bates, James M. Olson, Christopher Mehlin, et al.


  • Abstract 2443: Optides (optimized peptides), a new knottin-based cancer drug discovery platform

    by James M. Olson, Roland Strong, Christopher Mehlin, Colin Correnti

    Some of the highest value targets in cancer therapeutics involve protein:protein interactions that are difficult to inhibit with small molecule therapeutics. Peptide drug candidates offer an alternative, but many peptide drugs have poor pharmacokinetic properties and some are immunogenic. Knottin peptides have long been promoted as scaffolds for human drug discovery efforts because the exquisitely tight knot formed by disulfide bridges creates resistance to proteolytic and other forms of degradation. Furthermore, some knottins cross the blood brain barrier, the gut wall, or cell membranes which is ideal for certain targets. Unfortunately, creating knottins synthetically or in bacteria results in a large number of disulfide isomers, which has hampered research. We have created a mammalian expression system that enables production of most knottin scaffolds and variants of native knottins encoded in plant and animal genomes. The platform routinely produces approximately 10 mg/liter of near pure naked peptide, which is sufficient to conduct in vivo studies without major scale-up. The system is endotoxin free. In addition to building the platform, we identified over 200,000 new potential knottin peptides in various genomes, creating a rich collection of scaffolds from which to establish diversity libraries of native and optimized variants. These candidates have potential for targeting therapeutics to cancer cells as a solid tumor penetrating alternative to antibody drug conjugates. Optides also have potential to be developed as anti-cancer drugs themselves. The fact that knottin peptides are not substrates for resistance mechanisms such as p-glycoprotein pumps underscores the potential importance of this class of drugs for those with previously treated cancer. Citation Format: James M. Olson, Roland Strong, Christopher Mehlin, Colin Correnti. Optides (optimized peptides), a new knottin-based cancer drug discovery platform. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2443. doi:10.1158/1538-7445.AM2015-2443

  • Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31

    by Min Shen, Sophia Siu, Samantha Byrd, Kurt H. Edelmann, Neha Patel, Randal R. Ketchem, Christopher Mehlin, Heather A. Arnett, Haruki Hasegawa


  • A Diversity of Antibody Epitopes Can Induce Signaling through the Erythropoietin Receptor

    by Ai Ching Lim, Randal R. Ketchem, Luis Borges, Teresa Carabeo, Jane Carter, Joseph E. Hoover, Zhonghua Hu, Michael Wittekind, Hongxing Zhou, Christopher Mehlin

    Stimulation of red cell production through agonism of the erythropoietin receptor (EpoR) has historically been accomplished through administration of erythropoietin (EPO), the native ligand. The short half-life of EPO has led to the development of a variety of other agonists, including antibodies. It is of considerable interest to understand how these agents might activate the EpoR and whether or not it is important to bind in a manner similar to the native ligand. The binding epitopes of a panel of eight agonistic, single-chain antibody (scFv-Fc) constructs were determined through scanning alanine mutagenesis as well as more limited arginine mutagenesis of the receptor. It was found that while some of these constructs bound to receptor epitopes shared by the ligand, others bound in completely unique ways. The use of a panel of agonists and scanning mutagenesis can define the critical binding regions for signaling; in the case of the EpoR, these regions were remarkably broad.


  • Fusion Partners as a Tool for the Expression of Difficult Proteins in Mammalian Cells

    by Jue Zhang, Jane Carter, Sophia Siu, Jason W. O'NEill, Andrew H. Gates, John Delaney, Christopher Mehlin

    The expression of proteins which do not express well on their own can be enhanced by linking them to human serum albumin (HSA) or antibody crystallizable fragment (Fc). The constructs shown here are designed to secrete the proteins after transient transfection of mammalian cell lines. The fusion partners are appended to the N-terminus of the proteins and contain a linker designed to be proteolytically cleaved. Transient transfection and purification protocols are provided as well as experimental results with five interleukins.


  • Open Access

    Fusion partners can increase the expression of recombinant interleukins via transient transfection in 2936E cells

    by Jane Carter, Jue Zhang, Thien‐Lan Dang, Haruki Hasegawa, Janet D. Cheng, Irene Gianan, Jason W. O'NEill, Martin Wolfson, Sophia Siu, Sheldon Qu, et al.

    The expression levels of five secreted target interleukins (IL‐11, 15, 17B, 32, and IL23 p19 subunit) were tested with three different fusion partners in 2936E cells. When fused to the N‐terminus, human serum albumin (HSA) was found to enhance the expression of both IL‐17B and IL‐15, cytokines which did not express at measurable levels on their own. Although the crystallizable fragment of an antibody (Fc) was also an effective fusion partner for IL‐17B, Fc did not increase expression of IL‐15. Fc was superior to HSA for the expression of the p19 subunit of IL‐23, but no partner led to measurable levels of IL‐32γ secretion. Glutathione S‐transferase (GST) did not enhance the expression of any target and suppressed the production of IL‐11, a cytokine which expressed robustly both on its own and when fused to HSA or Fc. Cleavage of the fusion partner was not always possible. The use of HSA or Fc as N‐terminal fusions can be an effective technique to express difficult proteins, especially for applications in which the fusion partner need not be removed.


  • Structural Genomics of Pathogenic Protozoa: an Overview

    by Erkang Fan, David Baker, Stanley Fields, Michael H. Gelb, Frederick S. Buckner, Wesley C. Voorhis, Eric Phizicky, Mark Dumont, Christopher Mehlin, Elizabeth Grayhack, et al.

    The Structural Genomics of Pathogenic Protozoa (SGPP) Consortium aimed to determine crystal structures of proteins from trypanosomatid and malaria parasites in a high throughput manner. The pipeline of target selection, protein production, crystallization, and structure determination, is sketched. Special emphasis is given to a number of technology developments including domain prediction, the use of “co-crystallants,” and capillary crystallization. “Fragment cocktail crystallography” for medical structural genomics is also described.